Metabolic Dysfunction in Pulmonary Arterial Hypertension

Abstract

Previously considered a disease isolated to the pulmonary circulation, pulmonary arterial hypertension is now being recognized as a systemic disorder that is associated with significant metabolic dysfunction. Numerous animal models have demonstrated the development of pulmonary arterial hypertension following the onset of insulin resistance, indicating that insulin resistance may be causal. Recent publications highlighting alterations in aerobic glycolysis, fatty acid oxidation, and the tricarboxylic acid cycle in the pulmonary circulation and right ventricle have expanded our understanding of the complex pathobiology of this disease. By targeting these derangements in metabolism, numerous researchers are investigating noninvasive techniques to monitor disease activity and therapeutics that address the underlying metabolic condition. In the following review, we will explore pre-clinical and clinical studies investigating the metabolic dysfunction seen in pulmonary arterial hypertension.

Introduction

Pulmonary arterial hypertension (PAH) is a highly morbid and fatal illness defined by progressive pulmonary vascular obstruction, which ultimately leads to right ventricular failure and death [1–3]. While the disease is characterized histopathologically as an arteriopathy of small-to-medium-sized pulmonary arteries [4], PAH is increasingly being recognized as a systemic illness with a predilection for the pulmonary vasculature and right ventricle (RV) [5].

There is a growing body of evidence that a variety of systemic metabolic derangements are associated with, if not causative of, PAH. Much of the earlier research on this subject has focused on the role of insulin resistance (IR), glucose intolerance, and the metabolic syndrome (MS) on disease progression within the pulmonary circulation [6–9]. Several new discoveries over the past few years have illuminated more extensive metabolic dysfunction in PAH, as alterations in aerobic glycolysis, fatty acid oxidation (FAO), and the tricarboxylic acid (TCA) cycle [10] have been associated with PAH and the development of lipotoxicity in the RV [11]. Ongoing research will elucidate whether these metabolic alterations contribute to or result from pulmonary vascular disease.

As there are currently no known curative treatments for this devastating illness, pulmonary vasodilators, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostaglandins, are utilized to improve pulmonary vascular and right ventricular hemodynamics with varying degrees of success [12]. It is presently unclear whether treatments that target metabolic dysfunction in PAH will improve pulmonary vascular disease. Due to their ready availability and ease of administration, several FDA-approved metabolically-active drugs are being considered for the treatment of PAH, though none are known to have a beneficial effect in PAH. With improved understanding of the specific metabolic pathobiology of PAH, novel therapeutic modalities will hopefully emerge that treat the underlying disease state, rather than the secondary hemodynamic consequences. This review will focus on both basic science mechanisms of metabolic dysfunction and clinical knowledge regarding the potential role of altered metabolism in PAH.

Basic Mechanisms of Metabolic Disease in the Pulmonary Vasculature

BMPR2 Mutation and Insulin Resistance in Pulmonary Arterial Hypertension

Bone morphogenic protein receptor type 2 (BMPR2) is a protein kinase that, after binding its bone morphogenic protein (BMP) ligands of the transforming growth factor-β (TGF-β) superfamily, modulates tissue injury repair and many other signaling mechanisms including cytoskeletal function [13]. Germline mutations in BMPR2 are well-known causes of heritable PAH (HPAH) [14, 15], and are thought to induce PAH through increased apoptosis of pulmonary vascular endothelial cells [16] and uncontrolled proliferation of pulmonary vascular smooth muscle cells [17]. The inheritance pattern in HPAH is autosomal dominant with reduced penetrance (typically around 20%) [18]. While other novel genetic mutations associated with PAH have been discovered in recent years, approximately 80% of known HPAH is caused by BMPR2 mutations [5]. In fact, other forms of pulmonary hypertension have been associated with sporadic BMPR2 mutations, most notably idiopathic PAH (IPAH) [19], stimulant-associated PAH [20], and pulmonary veno-occlusive disease [21], and BMPR2 expression is reduced in IPAH even in the absence of germline BMPR2 mutations [22]. Given the clinical, histological, and genetic similarities between heritable and other forms of PAH [23], BMPR2 models of PAH are ideal for the study of molecular mechanisms of disease in PAH.

One known downstream target of BMPR2 is peroxisome proliferator–activated receptor-γ (PPARγ), a transcription factor that belongs to the nuclear receptor family, which has many downstream targets involved in vascular modeling and glucose homeostasis [24]. Two important downstream targets of PPARγ are apolipoprotein E (ApoE) [25] and adiponectin [26]. ApoE is predominantly involved in reverse cholesterol transport by macrophages [27], and adiponectin, a so-called adipokine as it is a cell-signaling protein secreted exclusively by adipocytes, is important for regulating endothelial inflammation [28]. Although their biochemical pathways are mostly unrelated, both proteins inhibit platelet-derived growth factor-β (PDGF-β) function.

While ApoE inhibits PDGF-β function by binding to lipoprotein-like receptor protein [29] and adiponectin binds the homodimer of PDGF-β [30], both decrease its bioavailability. The downstream consequences of heightened PDGF-β signaling on vascular smooth muscle cells are profound, as increased PDGF-β concentration leads to dysregulated vascular smooth muscle cell proliferation and survival due to upregulation of cell cycle-promoting genes via PDGF-β-dependent MAP kinase activation [31].

Circulating levels of PPARγ [32] and ApoE [33] have been noted to be reduced in PAH, either via BMPR2-mediated suppression or otherwise. It is important to note that aside from BMPR2 mutations or the presence of pulmonary vascular disease, reduced levels of PPARγ [34], ApoE [35], and adiponectin [36] have all been associated with a variety of pathologic metabolic states, such as obesity, type II diabetes mellitus (DMII), and IR.

Hansmann et al sought out to determine whether reduced levels of PPARγ and ApoE seen in PAH are causative, or merely biologic spectators [6]. By using an ApoE (−/−) mouse model, they observed that mice fed a high fat diet were prone to develop PAH, with a much more severe phenotype observed in the male cohort. They determined that the degree of PAH was inversely proportional to adiponectin levels, and since females had higher adiponectin levels than males at baseline, they were relatively protected from the development of PAH. IR developed in the male Apo (−/−) mice fed a high fat diet, and not in the corresponding female mice, indicative of the protective role of adiponectin in the development of IR as well. A fundamental observation from these data was that PPARγ activation with rosiglitazone raised adiponectin levels, improved insulin sensitivity, and ultimately reversed PAH in these mice.

Further supporting a role for adipokines in PAH, adiponectin knockout mice have also demonstrated significant vascular remodeling and PAH. Adiponectin (−/−) mice developed PAH in an age-dependent manner [37], and the phenotype was intensified when these mice were exposed to acute allergic airway inflammation independent of hypoxia [38]. The mechanisms through which airway disease stimulates pulmonary vascular disease in this model are as yet unclear, but these data suggest that adipokines are active in the lungs and may influence pulmonary vascular disease.

Our group has demonstrated a high degree of IR in a transgenic rodent model of inducible mutant BMPR2 overexpression. In this model, transgenic mice developed early IR (within two weeks of transgene activation and prior to development of PAH) associated with rapid weight gain [39]. We further found tissue markers of lipid deposition, including fat staining in the peripheral muscles [40]. Similarly to Apo (−/−) mice, BMPR2 mutant mice fed a high-fat diet developed a more severe PAH phenotype with higher penetrance of the disease [40]. Furthermore, we demonstrated that BMPR2 mutant mice developed glucocorticoid receptor translocation abnormalities, which led to glucocorticoid resistance that may underlie some of the metabolic findings in this model.

These data taken together are interesting for several reasons. First, they demonstrate that BMPR2 signaling is linked downstream to PPARγ. Since PPARγ is a known “master regulator” of insulin sensitivity, dysfunctional BMPR2 expression may influence cellular glucose homeostasis. Additionally, in a model of BMPR2 mutation, IR develops before pulmonary hypertension, suggesting a causative role for IR in the development of pulmonary vascular disease. Finally, these studies show that traditional animal models of IR such as the ApoE or adiponectin (−/−) mice develop pulmonary hypertension, demonstrating that IR may promote pulmonary vascular disease independent of BMPR2 signaling (Figure 1).

Figure 1.

Insulin resistance and PAH. BMPR2, PPARγ, ApoE, and APN knockout mice all lead to the development of insulin resistance (IR) prior to pulmonary arterial hypertension (PAH), and IR is commonly associated with PAH in human studies. BMPR2 mutations also lead to right ventricular lipotoxicity. BMPR2 = bone morphogenic protein receptor 2, PPARγ = peroxisome proliferator–activated receptor-γ, ApoE = apolipoprotein E, APN = adiponectin.

Other Affected Metabolic Pathways in Pulmonary Arterial Hypertension

IR seems to play a major role in PAH and has thus far been the best studied, however observed derangements in glycolytic, TCA cycle, carnitine, fatty acid, and glutamate metabolism indicate a more widespread metabolic disease state beyond glucose homeostasis. It has been noted that aerobic glycolysis, otherwise known as the “Warburg effect”, is highly prevalent in patients with PAH [41]. The Warburg effect is considered an adaptive mechanism exhibited by rapidly proliferating cells (notably cancer cells) that allows for unrestrained growth [42]. It is also the fundamental principle behind positron emission tomography-computed tomography (PET-CT) detection of radioactively labeled fluorodeoxy-D-glucose (FDG) uptake in such cells [43]. While the ATP generated per glucose molecule in glycolysis is far less than via mitochondrial respiration, the reliance on less efficient catabolism may have some advantages when glucose uptake is not rate-limiting [44].

Marsboom et al explored alterations in glucose metabolism in two different mouse models of PAH, both the monocrotaline and SU5416 with chronic hypoxia models. FDG uptake in lung tissue as determined by PET-CT scan increased simultaneously with the development of PAH [45], suggesting that increased glucose turnover can be detected non-invasively by FDG uptake and is a relatively early feature of pulmonary vascular disease in these rodent models. The observed increase in aerobic glycolysis was found to be secondary to increased glucose transporter 1 expression in PA endothelial and smooth muscle cells in vivo and in vitro, partly due to increased hypoxia-inducible factor-1α (HIF-1α) expression.

These largely mechanistic studies have focused on the glucose metabolic pathway, but other fundamental areas of metabolism have been less explored. We studied the metabolic profile of pulmonary microvascular endothelial cells (PMVEC) in humans and BMPR2 mutant mice. Fessel et al showed that human PMVEC transfected with BMPR2 vector were noted to have extensive alterations in their gene expression when compared to empty vector controls [10]. Nearly one-half of the altered genes regulated small molecule metabolism, and there was evidence of increased aerobic glycolysis and decreased FAO. Furthermore, we observed increased pentose phosphate pathway activation, decreased carnitine metabolism, decreased TCA cycle enzymatic activity distal to citrate, and increased catabolism of peptides and amino acids. This unbiased discovery approach has demonstrated that multiple metabolic pathways are affected in cells with a mutation known to cause PAH. Although failure of adequate glucose homeostasis is an important feature of PAH, it is likely not the only metabolic derangement in this disease.

Basic Mechanisms of Right Ventricular Metabolic Disease

Altered metabolism is not isolated to the PMVEC or PA smooth muscle cells in PAH, but is also seen in the RV. It is clear that different animal models of PAH have varying effects on the RV. Some models, such as the pulmonary artery banding (PAB) model, induce an early and adaptive model of RV hypertrophy soon after the intervention. Other models, such as those that utilize the endothelial cell toxin monocrotaline, stimulate early and dysfunctional changes in the RV, such as dilation and fibrosis [46, 47].

Exploiting this distinction between models, investigators have shown that the RV of mice treated with PAB as compared to a SU5416 and chronic hypoxia model demonstrate different metabolic profiles [48]. Specifically, the RV of mice treated with SU5416 and chronic hypoxia had decreased expression of PPARγ, its cofactors, and its target genes. There was also a qualitative and quantitative reduction in mitochondria associated with reduced oxidative capacity. These changes were not found in the corresponding mice treated with PAB.

In contrast, other groups have observed that even the hypertrophied RVs of mice that have undergone PAB demonstrated a shift away from glucose oxidation towards aerobic glycolysis and FAO [49]. While FAO is the preferred form of ATP-generation in cardiomyocytes in the healthy RV [50, 51], inhibitors of FAO (trimetazidine and ranolazine) induced an increase in cardiac output and exercise capacity, with a regression of established RV hypertrophy in the PAB model. Inhibitors of FAO may improve RV hemodynamics by shifting RV metabolism towards glucose oxidation, by the so-called “Randle cycle” [52], thus improving the oxidative metabolism of RV cardiomyocytes [47]. The long-term consequences of suppressing FAO in the heart, however, are presently unstudied and may not be beneficial based on the normal metabolic preferences of the heart.

In the case of PAH associated with germline BMPR2 mutations, the metabolic effects would be predicted to affect all tissues of the body to varying degrees. The RV changes seen in BMPR2 mutant mice are illustrative of the breadth of metabolic alterations in the context of PAH, as we have demonstrated a maladaptive RV response that is associated with marked myocardial lipotoxicity. The compensatory concentric RV hypertrophy that is seen in PAB-treated mice and smooth muscle-specific BMPR2 mutant mice is mitigated in mice with a systemic BMPR2 mutation, despite moderate increases in PA pressures [11]. The RVs of these mice demonstrated extensive lipid deposition (notably triglycerides and ceramides) within the cardiomyocytes. Circulating lipids were not elevated in these mice, and extracellular RV and left ventricle (LV) lipid deposition was minimal. This effect, though profound, could be reversed qualitatively and quantitatively by metformin administration.

The reason behind this observed lipotoxicity is under active investigation, however it is almost certainly multifactorial. We have shown that there is increased expression of CD36, a fatty acid transporter, in the RV of BMPR2 mutant mice and control mice fed a high-fat diet [53], which may be responsible for the increase in fatty acid entry into RV cardiomyocytes. Expression patterns in human RVs have suggested suppression of FAO [11], thus the utilization of fatty acids may be reduced at a mitochondrial level in cardiomyocytes with BMPR2 mutations [10]. The increase in fatty acid uptake, coupled with potentially reduced utilization, necessitates the conversion of these free fatty acids into complex lipids, such as triglycerides and ceramides [54]. Once in the cytoplasm of RV cardiomyocytes, these lipids fail to be transported out of the cells and may mediate the RV dysfunction seen in these mice. The mechanisms of how lipotoxicity alters RV hypertrophy and compensation are currently unknown and are active areas of exploration. Development of RV-specific metabolic therapies is the ultimate goal of these studies of lipotoxicity in the RV of patients with PAH.

Human Studies Involving Metabolic Disease and the Pulmonary Vasculature

Insulin Resistance in Pulmonary Arterial Hypertension

While IR can be broadly defined as an abnormal clinical response to a physiologic amount of insulin, there is a wide array of clinical conditions associated with it, ranging from frank DMII to the MS [55]. While the American Diabetes Association has identified several modalities for the diagnosis of DMII, notably a hemoglobin A1c greater than 6.5 [56], the diagnosis of the MS is less clearly defined. The most unified definition was jointly published by several American and international organizations in 2009, and includes the presence of or treatment for three out of the following five entities: elevated waist circumference, elevated triglycerides (TG), reduced high density lipoproteins (HDL), elevated blood pressure, or elevated fasting blood glucose [57].

DM and the MS have a steadily increasing prevalence around the USA and world, occurring in approximately 1/8 and 1/3 of American adults, respectively [58, 59]. IR is thought to be the underlying defect in both conditions [60], and several biomarkers have been validated as reasonable surrogates for IR, particularly an elevated TG/HDL ratio and the homeostasis model assessment (HOMA), which utilizes fasting glucose and insulin levels to estimate pancreatic beta cell function and insulin sensitivity [61–63].

Numerous investigators have demonstrated that high levels of pro-inflammatory biomarkers, such as C-reactive protein, interleukin 6, and myeloperoxidase, are seen in conditions associated with IR [64–67], and this inflammatory milieu is thought to underlie the associated endothelial dysfunction and vascular disease seen in patients with obesity, DM, and the MS. While much is known about the association of IR and vascular disease in the systemic circulation [68, 69], the role of IR and other metabolic derangements on the pulmonary circulation and RV is an emerging field (Table 1).

Table 1.

Widespread zmetabolic dysfunction in PAH. The following systemic and right ventricular defects in metabolism have been identified in humans with pulmonary arterial hypertension (PAH). While very few targeted therapeutics have been studied in humans, animal models and case reports have demonstrated potential metabolic targets.

Tissue(s) Affected	Metabolic Defect	Supporting Data and References	Investigative Therapeutics
Systemic Changes	IR	More IR in PAH subset of NHANES vs. age-matched controls [7] Decreased short-term survival in PAH with IR vs. insulin sensitivity [7] More IR in ASD patients with vs. without PH [79]	Metformin (enrolling patients, NCT01884051) PPARγ agonist (i.e. Rosiglitazone, no clinical trials in humans performed or enrolling) When indicated, Roux-en-Y gastric bypass in the morbidly obese [72]
	Glucose Tolerance	Elevated A1c in PAH vs. age-matched controls [8] Decreased long-term survival in PAH with A1c >5.7 vs. <5.7 [9], and with DMII vs. without [80]
	HDL	Reduced HDL in PAH vs. controls [71] Decreased 1.5 year survival in PAH with low vs. normal HDL [71]	Simvastatin ineffective in the ASA-STAT trial, although changes in HDL not reported [84]
	Altered TCA Cycle	Increased IDH 2/3 activity in HPAH vs. controls, with decreased TCA intermediates distal to citrate [10]	No known therapy
	Adiponectin	Increased adiponectin in PAH vs. age-, sex-, and BMI-matched controls, although this may represent developed resistance [74]	When indicated, Roux-en-Y gastric bypass in the morbidly obese [72]
	Leptin	Increased leptin and leptin receptor expression on regulatory T cells in PAH vs. controls [78]
	Ghrelin	Reduced ghrelin in ASD patients with vs. without PH [79]
Right Ventricle	Aerobic Glycolysis	Gene expression demonstrates reliance on aerobic glycolysis over FAO and TCA cycle in HPAH vs. healthy and dilated cardiomyopathy control RVs [11]	No known therapy
	FAO
	Altered TCA cycle
	Lipid Deposition	Increased deposition of lipids in HPAH RV cardiomyocytes [11]	Metformin (enrolling patients, NCT01884051)

Validating the associations seen between IR and PAH in animal models, there is a growing body of data supporting these findings in humans. When compared to age-matched controls from the National Health and Nutrition Examination Survey (NHANES) database, non-diabetic female patients with PAH had significantly more IR assessed by the TG/HDL ratio [7]. Interestingly, when compared with insulin sensitive PAH patients, IR PAH patients had the same age and weight profile; however, when compared with the IR control patients, the IR PAH patients were both younger and less frequently overweight. Our group has shown that as many as 2/3 of non-diabetic patients with PAH will demonstrate some degree of glucose intolerance, defined as a hemoglobin A1c greater than 6.0 [8]. In fact, 15% of the patients evaluated were newly diagnosed with DMII because of the analysis. Similar to what Zamanian et al demonstrated, glucose intolerance in this population seems to be independent of other risk factors for IR, as age and BMI between PAH patients with and without glucose intolerance were equal. While IR and the MS are highly associated with PAH, the association is even stronger for pulmonary venous hypertension, with two of the three features of the MS seen in nearly all patients with PVH [70].

IR and disordered glucose metabolism also appear to impact survival in PAH. In both prior studies, while their degree of IR did not correlate with individual metrics of disease severity, IR PAH patients, as determined by both TG/HDL and hemoglobin A1c, have decreased short- and long-term survival [7, 9]. Aside from the TG/HDL ratio, a low HDL level was independently associated with worse outcomes in PAH [71].

While there are no published therapeutic trials in humans aimed at improving IR in PAH, we reported a potentially illustrative case of a female with IPAH and morbid obesity treated with laparoscopic Roux-en-Y gastric bypass surgery [72], an experiment of nature involving surgical correction of IR in PAH. Following surgery, and prior to any substantial weight loss, her pulmonary vascular and RV hemodynamics greatly improved. This trend continued as she sustained significant weight loss, and was paralleled with improved insulin sensitivity and lipid metabolism. Whether this pulmonary vascular improvement can be achieved by pharmacologic adjustments of metabolism or solely by gastric bypass is presently unknown. Moreover, as this is only a single case, bariatric surgery cannot presently be recommended as a therapy for PAH.

Other Affected Metabolic Pathways in Pulmonary Arterial Hypertension

Our group has shown that humans with HPAH have altered gene expression profiles in cultured lymphocytes from peripheral blood that predominantly affect the metabolic pathway [11]. In examining the RVs and serum from HPAH patients, we have also demonstrated reduced FAO and TCA cycle enzymatic expression compared with healthy controls [10, 11] and patients with dilated cardiomyopathy [11], favoring aerobic glycolysis instead. These data show conserved alterations in metabolic pathways across tissue types.

On the other hand, when the explanted lungs of patients with severe PAH following lung transplant were analyzed, Zhao et al noted an overall decrease in glycolysis and increase in TCA cycle activity [73]. The reason for this discrepancy is not entirely clear, however our patients all had HPAH at a presumed time of steady state, whereas the patients evaluated by Zhao et al had very advanced disease without mention of BMPR2 status.

Adipokines have recently been explored in PAH patients as biomarkers, if not mediators, of PAH. Adiponectin has been shown to be elevated in patients with PAH compared to age-, sex-, and BMI-matched controls in a large series [74]. At first glance this seems counterintuitive, as animal models of the disease demonstrate a protective role of adiponectin [6, 75, 76]. However, there is evidence of reduced survival in patients with left-sided heart failure and elevated adiponectin [77], so there may be a developed resistance to the once-protective protein similar to IR seen in the MS and DMII. Humbert et al investigated the role of another adipokine, leptin, in PAH. Compared to controls, PAH patients had increased serum leptin levels, with much of the leptin secretion occurring in the pulmonary endothelial cells [78]. Furthermore, the percentage of regulatory T cells expressing the leptin receptor was increased in PAH, with reduced function of these cells, indicating a leptin-dependent immunomodulatory effect in PAH [78]. Other reports have noted reduced levels of ghrelin, and reduced ghrelin-to-obestatin levels, in patients with PAH secondary to an ASD [79], further demonstrating the complex interplay between PAH and the digestive hormones.

Human Studies Involving Metabolic Disease and the Right Ventricle

Clinical data in humans has confirmed increased lipotoxicity and glycolytic activation in the RVs of patients with PAH. Similar to the RVs of BMPR2 mutant mice, humans with HPAH have evidence of lipid deposition limited to the cardiomyocytes of the RV, with sparing of the extracellular space and LV [11]. We have recently demonstrated that in HPAH and IPAH, patients with a diagnosis of DM had worse outcomes that appeared to correlate with markers of worse RV function, suggesting a negative impact of DM on RV stress response [80]. Interestingly, while the presence of IR was not associated with echocardiographic RV dysfunction in PAH in Brunner et al’s recent analysis, diastolic dysfunction of the LV was noted [81].

Building upon the PET-CT studies done on the lung tissue of mice with PAH, several authors have shown that PET-CT scans can also detect an increase in FDG uptake in the RV of patients with PAH [82, 83]. With the exception of patients receiving β-adrenergic receptor blockade, RV FDG uptake correlated well with worsening pulmonary hemodynamics and echocardiographic changes, and appeared to be HIF-1α-mediated. It appears that at least some of the increased RV glucose uptake could be attributed to a corresponding reduction in LV glucose uptake secondary to worsening cardiac output from LV under-filling [83].

Conclusions

Long known to be causal of an inflammatory cytokine profile, endothelial dysfunction, and systemic cardiovascular disease, IR and dysregulated glucose metabolism are now being recognized as major contributors to the development of pulmonary vascular disease. Through translational research involving animal models and human studies, we now recognize that alterations in glucose and fatty acid metabolism due to IR and aerobic glycolysis are associated with the development of uncontrolled vasoconstriction in the pulmonary circulation and RV lipotoxicity and dysfunction in patients with PAH.

While inherited or sporadic BMPR2 mutations seem to be partially responsible, as BMPR2 and its downstream targets are intimately involved in glucose homeostasis, many of the PAH animal models have demonstrated that the disease phenotype worsens with certain modifications, such as a high-fat diet. This seems to indicate a “second hit” phenomenon for the development of PAH, with the penetrance and severity of the disease dependent on environmental factors (such as poor diet or a sedentary lifestyle) in the presence of altered BMPR2 signaling.

Exploiting the altered glucose metabolism in PAH has opened the door for noninvasive measures to diagnose and follow the disease. The use of PET-CT scans may eventually minimize the need for direct hemodynamic data to monitor response to therapy or stratify patients at greater risk of developing RV failure. While it seems promising, this noninvasive modality has yet to replace the right heart catheterization as the gold standard for the diagnosis of PAH.

Therapeutically targeting this pathologic metabolic condition with medications such as thiazolidediones, metformin, or inhibitors of FAO is an area of active research by numerous investigators. While pulmonary vasodilators will have a role in treating this condition for the foreseeable future, modifying the metabolic dysfunction of PAH in the pulmonary vasculature and RV is an exciting prospect for the treatment of this devastating illness and the goal of future pre-clinical and human studies.